The review identifies STAT1 as one of the key interferon-stimulated genes relevant to glioblastoma pathology and as a possible biomarker or therapeutic target context.
First-pass extracted concept
STAT1
Candidate: concept label1 source documents4 linked claims
Live refresh every 5sNext refresh in 5s
Extracted Explainers
What problem it solves
Evidence Snippets
Supporting Sources
Linked Claims
In glioblastoma, deregulated elements of canonical IFN-b3 signaling result in overexpression of STAT1-target interferon-stimulated genes associated with tumor progression.
Quoted textsource-backed
In glioblastoma, a highly aggressive primary brain tumor in adults, elements of IFN-b3 canonical signaling are deregulated, resulting in the overexpression of STAT1-target ISGs associated with tumor progression.
STAT1, IRF1, PD-L1, IDO1, and ISG15 are highlighted as genes involved in glioblastoma pathology.
Quoted textsource-backed
This mini-review highlights key ISGs, including STAT1, interferon regulatory factor 1, programmed death-ligand 1, indoleamine 2,3-dioxygenase 1, and interferon-stimulated gene 15, involved in the pathology of glioblastoma.
Canonical IFN-b3 signaling through the JAK1/2-STAT1 axis induces expression of interferon-stimulated genes.
Quoted textsource-backed
The canonical signaling of interferon gamma (IFN-b3) through the Janus kinase 1 and 2-signal transducer and activator of transcription 1 (STAT1) axis leads to the expression of several interferon-stimulated genes (ISGs)
The highlighted IFN-b3 pathway-associated genes may serve as biomarkers and may have therapeutic potential in glioblastoma.
Quoted textsource-backed
These genes may serve as valuable biomarkers and have therapeutic potential for targeting IFN-b3 signaling in this malignancy.